



Cynghrair Niwrolegol Cymru
Wales Neurological Alliance



Cynulliad Cenedlaethol
Cymru
National Assembly for
Wales

Cross-Party Group for Neurosciences **Grŵp Traws-bleidiol Niwrowyddonol**

Minutes 4th July, 11am to 1pm

Name	Organisation/Constituency or Region
Mark Isherwood AM (Chair)	
Andrew RT Davies AM	
Ruth Cooke	Allergan Pharmaceuticals
Nia James	Biogen
Cassy Ashman	BRAIN, Cardiff University
Mark Wardle	Cardiff and the Vale UHB
Malisa Pierri	Cardiff and the Vale UHB
Dr Biju Mohammed	Cardiff and the Vale UHB
Dr Sandip Raha	Cwm Taf and Morgannwg UHB
John Meredith	Dystonia Society
Bob Walsh	Dystonia Society
Andrea Bellamy	Dystonia Society
Greta Evans	Dystonia Society
Dawn Turner	Dystonia Society
Alyson Courtenay	Dystonia Society
Jane Waters	Dystonia Society
Sarah Dorian	Epilepsy UK
Daniel Jennings	Epilepsy UK
Anna MacLean	Migraine Mission Wales
Gwyneth Lewis	Migraine Mission Wales
Lynne Hughes	MS Society
Matthew Witty	MS Society
Sian Tucker	MS Society
Fiona MacDonald	MS Society
Ian Chandler	MNDA
Ana Palazon	Parkinsons UK
Rachel Williams	Parkinsons UK
Tony Hillier	Parkinsons UK
Jill Hillier	Parkinsons UK
Kate Steele	SHINE
Ayesah Khan	SHINE
Gareth Cottrell	Swansea Bay/ Hywel Dda UHB
Dr Chris Rickards	Swansea Bay/ Hywel Dda UHB
Stephen Evans	Swansea Bay/ Hywel Dda UHB
Rebecca Brown	Wales Neurological Alliance
Claire Nelson	WHSSC
Laura Courtney	Wales Neurological Alliance
Lesley Wilson	
Lauren Evans	

Apologies	
Mike Hedges AM	
Dawn Bowden AM	
Helen Mary Jones AM	
Dr Dai Lloyd AM	
Vikki Howells AM	
Dr Owen Pearson	
Prof Neil Richardson	
Angela Burns AM	

Welcome and Introduction:

Mark Isherwood AM, Chair of the Cross Party Group on Neurological Conditions introduced the oral evidence session reminding us of the terms of reference:

- To examine the progress made on implementing the plan across each of the local health boards.
- Whether Wales is on course to achieve the outcomes and performance measures, as set out in each of the chapters of the Neurological Conditions Delivery Plan, by 2020.
- Whether patients across Wales can access the care required (for example timely diagnosis, access to diagnostics and treatments, palliative and end of life care) in an appropriate setting and in a timely manner
- The level of collaborative working across sectors, especially between the NHS and third sector, to ensure patients receive effective person - centred care from multi-disciplinary teams.
- Whether the current level of funding for neurological services is appropriate, used effectively and provides value for money.

Evidence has so far been submitted to this inquiry by a wide range of stakeholders, including:

- Individuals living with neurological conditions;
- Charities representing people affected by neurological conditions;
- Royal Colleges;
- The Wales Neurological Alliance; and
- The Neurological Conditions Implementation Group.

The purpose of this oral evidence session is to capture the views and experiences of a range of stakeholders about the implementation and impact of the Neurological Conditions Delivery Plan. It will also provide an opportunity to discuss practical solutions for future action.

Table discussions:

Attendees were then asked to consider the following questions at each table.

Question 1: Do you feel the Neurological Conditions Delivery Plan has delivered enough change for people with neurological conditions in Wales? Can you give examples to illustrate your answer?

Question 2: In what ways do you think the Neurological Conditions Delivery Plan has been most successful? Can you give any examples?

Question 3: In what ways do you think the Neurological Conditions Delivery Plan has been least successful? Can you give any examples?

Question 4: Do you have any suggestions for future action which could be taken to improve treatments, services and support for people with neurological conditions in Wales?

Question 5: Do you have any comments on the current level of funding for neurological services in Wales? What are your views on whether funding for neurological services is used effectively and provides value for money?

Question 6: Do you have any comments on the way in which the NHS works together with other organisations, like charities, in providing person centred care to people with neurological conditions?

Closing remarks

Mark Isherwood AM thanked everyone for coming and reminded people that further evidence sessions will be held in October and November with the final report due January 2020.